HYBRID EVENT: You can participate in person at Baltimore, MD, USA or Virtually from your home or work.

2nd Edition of International Conference on Gastroenterology

October 21-23, 2024, Baltimore, Maryland, USA

October 21 -23, 2024 | Baltimore, MD, USA
Gastro 2024

Sara Seifouri

Speaker at Gastroenterology Conferences - Sara Seifouri
St. Thomas NHS Foundation Trust, United Kingdom
Title : Efficacy of sertraline on the symptoms and quality of life in patients with irritable bowel syndrome: A single-blinded and parallel designed randomized controlled trial

Abstract:

Introduction:
Irritable Bowel Syndrome (IBS) is one of the most common digestive system disorders with a worldwide prevalence of 5-20%. The actual cause of IBS is still unknown, as it is considered to be related to both psychological and physiological components. It is thought to occur due to disparity in the relationship of the gut-brain axis, which is modulated by serotonin. A wide range of therapeutic approaches have been recommended for this disorder, one of which were antidepressants. Antidepressants were suggested to treat long-lasting IBS. This study aims to evaluate the effect of the administration of Sertraline in IBS patients on their symptoms and quality of life.

Methods:
In this clinical trial, 60 patients diagnosed with IBS (30 in control group and 30 in case group) were recruited in a university hospital in Iran in 2018. The demographic indicators were not significantly different within the two groups. The control group patients were treated with Colofac 200 mg while, the case group received Colofac 200 mg and Sertraline 50-200 mg. These patients were followed for 8 weeks. The Hospital Anxiety and Depression Scale (HADS), Visual Analogue Scale (VAS) and 36-item Short Form survey (SF-36 questionnaire) were used for assessment of the research endpoints including anxiety and depressive symptoms, pain and quality of life. HADS consists of 14 items, including seven items related to anxiety symptoms and seven items related to depression symptoms. The SF-36 questionnaire measures health-related quality of life, taking into account both physical and mental aspects. Data was analyzed with SPSS v.22. ANNOVA and Mann-Whitny test were used for data analysis.

Results:
The patients in the case group showed a significant decrease in HADS (p<0.001) and VAS (p=0.001) score at week eight compared to the control group cases. The patients in the case group also showed a significant increase in two of the SF-36 criteria compared to that of the control group. The SF-36 results indicated a significant improvement in both emotional well being (p=0.018) and limitations due to physical health (p=0.00).
Conclusion: This study demonstrated that administration of Sertraline increased the general health and quality of life in patients with IBS, in addition to decrease in pain in these patients.

Audience Takeaway Notes:

  • Despite the significant impact of IBS on quality of life, treatment options are often limited and may not provide adequate relief for all patients. SSRIs have shown promising effects in cases of delayed intestinal motility symptoms of IBS and a better side-effect profile than TCAs. Therefore, In this presentation, we hope to further clarify the potential benefits of using sertraline to alleviate pain and enhance the quality of life in individuals with IBS. 

  • Latest research findings will be discussed, highlighting the efficacy of Sertraline and other SSRIs in managing IBS symptoms.

  • The possible mechanisms by which Sertraline may exert its effects on IBS symptoms will beexplored, providing valuable insights for healthcare professionals seeking to optimize patient care.

  • By attending this presentation, participants will gain a deeper understanding of the role of Sertraline in the management of IBS and how this treatment option can positively impactthe lives of many suffering from this chronic condition. The insights shared in this session have the potential to enhance clinical practice and improve outcomes for individuals struggling with IBS.

Biography:

Dr. Seifouri conducted the above-mentioned study for her thesis while studying medicine at Babol University in Iran, graduating with an MD in 2018. She subsequently began providing medical services as a general practitioner in a deprived area of Iran. Following this, she joined the research group of Prof. Nakhjavani at the Institute of Endocrinology and Metabolism Research Center (ERMC), Tehran University of Medical Sciences. Since 2023, she has been working as a Clinical Fellow Doctor at Guy’s and St. Thomas’ NHS Foundation Trust, London, UK. She has authored 6 research articles, and remains deeply dedicated to ongoing research pursuits.

Watsapp